Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia

N/ACompletedNCT02520895

Hospices Civils de Lyon98 enrolled

Overview

RIPAL is a prospective cohort study, which main goal is to define T and B immune repertoire diversity and magnitude in patients with non-Hodgkin lymphoma of high and low grade and chronic lymphocytic leukemia before and after treatment, and to evaluate the association of these parameters with clinical patient data and outcomes.

Constitution of a prospective cohort of 128 patients with 8 different groups of patients. This protocol is designed to evaluate a new tool for detecting the diversity of the repertoire T and B in patients with hematological disease. This in vitro diagnostic device is consisting of molecular biology kits Human ImmunTraCkeR® and Human Immun'IgH® and the analysis tool NDL®

Study Type

OBSERVATIONAL

Enrollment

Conditions

LYMPHOMA

Interventions

blood samplingsBIOLOGICAL

patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 Years and older * Subjects with a diagnosis of large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, MALT, marginal zone, Waldenstrom's disease, chronic lymphocytic leukemia, T-cell lymphoma, anaplastic, cytotoxic or peripheral unspecified angioimmunoblastic. * Have signed an informed consent for participation in the study and preservation of blood samples for biomedical research. * Accept to appear in consultation biological samples at the sampling points corresponding to its group. * The benefits of social security. Exclusion Criteria: * Subjects with a diagnosis of Hodgkin disease * Subjects with a diagnosis of T-prolymphocytic leukemia * Subjects with a diagnosis of Burkitt's lymphoma * Subjects with a diagnosis of lymphoblastic lymphoma * Subjects who had prior-treatment for hematological disease * Patients under judicial safeguards

Locations (1)

Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud

Pierre-Bénite, France

Outcomes

Primary Outcomes

change in variations of the T and B cell repertoire in patients with lymphoid blood disease under treatment

results given by the technical Immun'IgH® Human and Human ImmunTraCkeR® and score NDL® The 2 criteria for obtaining the data are the diversity and intensity of the immune repertoire: The intensity of the signal corresponds to the frequency of VJ rearrangements detected in the samples. It is expressed in Arbitrary Units. The diversity corresponds to the number of different VJ rearrangements detected compared to all theoretical VJ rearrangement. It is expressed in percentage.

Time frame: from D0 to 18 months

Secondary Outcomes

performance of the mapping of the immune repertoire to predict treatment response

The response to initial treatment will be confronted with the results given by the technical Immun'IgH® Human and Human ImmunTraCkeR® and score NDL® Response to treatment will be assessed by the local treating physician as complete response (CR), unconfirmed complete response (CRu), partial response (PR), stable disease, or progressive disease (PD) in accordance with the International Workshop Standardized Response Criteria for Non-Hodgkin Lymphoma and International Workshop Standardized Response Criteria for Chronic Lymphocytic Leukemia.

Time frame: from D0 to 18 months

performance of the mapping of the immune repertoire to predict progression free survival

the progression free survival will be confronted with the results given by the technical Immun'IgH® Human and Human ImmunTraCkeR® and score NDL® For all groups except group 8 (LLC untreated): the progression free survival is defined as the number of months elapsed between the first day of treatment (D0) and progression For The group 8: the progression free survival is defined as the number of months elapsed between the first day of the consultation (D0) that led to the confirmation of diagnosis and the date of first treatment.

Time frame: from D0 to progression

performance of the mapping of the immune repertoire to predict the risk of infection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.